Introduction
============

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and remains the second-leading cause of cancer-related death in men ([@r1],[@r2]). Despite advances in screening for and early detection of prostate cancer, a large portion of men continue to present with advanced or metastatic disease-approximately 20% of men in recent reports ([@r3]). Indeed, the morbidity from this disease remains high, with more than 29,000 prostate cancer related deaths in 2013 alone ([@r1]).

Androgen deprivation therapy (ADT), the standard of care for patients with biochemical recurrence after definitive primary therapy, locally advanced disease or metastatic disease, has been demonstrated to provide an initial benefit, but the majority of patients will progress to castration-resistant disease within 2-3 years ([@r4]).

Castration-resistant prostate cancer (CRPC), previously called hormone-refractory prostate cancer, is now understood to be a progression of disease despite medical or surgical castration. The paradigm shift is due to the understanding that CRPC is not hormone-refractory---in fact, the androgen axis continues to play an important role in the function and growth of CRPC. Indeed, while other pathways can contribute to castration-resistance, the androgen receptor (AR) remains the most important driver in the continuum of CRPC.

Understanding the mechanisms of resistance that cause hormone-naive prostate cancer to progress to castration-resistance is the key to developing future therapy. In this review, we will review the current knowledge regarding the mechanisms leading to castration resistance, the agents currently available for treatment of CRPC, and the mechanisms of resistance against these agents.

Background
==========

Understanding the androgen axis is a key component to understanding the mechanisms by which castration-resistance develops.

Androgen receptor (AR)
----------------------

The *AR* gene on Xq11-12 encodes for a 110 kDa nuclear receptor with four distinct functional motifs---the amino-terminal domain (NTD), DNA-binding domain, hinge region, and ligand-binding domain (LBD) ([@r5]-[@r7]). The cytoplasmic receptor is bound by heat-shock proteins (specifically HSP90 chaperone complex) in the inactive state ([@r8]). Androgen binding, specifically dihydrotestosterone (DHT) or testosterone, to the LBD causes a conformational change that leads to dissociation of the HSP90 complex, homo-dimerization of the receptor, translocation to the nucleus, and binding to androgen-response elements (AREs) in the promoter region of androgen-regulated genes ([@r6],[@r9]). This interaction with the promoter region is under the influence of many transcriptional coregulators. Over 150 proteins have been identified ([@r10]), and many are enzymes (histone acetyltransferases, methyltransferases, kinases) that act to open the chromatin structure to promote transcription.

Androgens
---------

Prostate cancer growth and survival depends on androgens, the major ligands for the AR. Testosterone is the primary circulating androgen, with approximately 90% produced by Leydig cells in the testes and 10% produced by the adrenal cortex. Only a small portion (3%) of circulating testosterone is unbound and functionally active---the remainder is bound and sequestered by sex-hormone binding globulin and albumin. However, testosterone is not the primary functionally active androgen in the prostate microenvironment. Following diffusion into the cytoplasm, testosterone is converted by the enzyme 5α-reductase to DHT, which has a five-fold higher affinity for the LBD of AR ([@r11]-[@r13]).

Physiologic levels of androgens are required to promote growth and prevent apoptotic death. Therefore, the pathways under AR influence are varied, but focus on the functions of the luminal epithelial cells, including production of seminal fluid proteins such as prostate-specific antigen (PSA) and multiple genes in the metabolic pathway leading to increased protein and lipid synthesis ([@r14]-[@r16]).

Steroidogenesis, which leads to androgen production, is an important pathway to understand, as it can be fundamentally altered in CRPC. Testosterone is produced by the testes and adrenal gland, and then converted in the cytoplasm to DHT via the activity of 5α-reductase ([@r17]). However, in the presence of ADT, studies have demonstrated persistent levels of intratumoral DHT ([@r18]-[@r21]), suggesting that altered steroidogenesis pathways have been activated ([@r20]). Adrenal testosterone sources, unaffected by ADT, and intratumoral *de novo* androgen synthesis may be sources of persistent ligand-dependent AR activity in CRPC ([@r22]).

Androgen deprivation therapy (ADT)
----------------------------------

Since Huggins and Hodges ([@r23]) first demonstrated the dependence of prostate cancer on androgen signaling, ADT through either medical or surgical castration has been the standard of care for metastatic and locally advanced disease. Surgical castration, or bilateral orchiectomy, removes testicular androgens from circulation by removal of the source. Medical castration is achieved through the use of different classes of agents. LHRH agonists and antagonists deplete the pituitary production of luteinizing hormone (LH) through negative feedback or competitive inhibition, respectively, which in turn prevents testicular testosterone production ([@r24]). Anti-androgens work as competitive inhibitors at the LBD of AR, thereby preventing androgen stimulation of AR. These agents, in conjunction, provide complete androgen blockade ([@r25],[@r26]).

Castration resistance
---------------------

Despite the initial response to androgen blockade, all patients will eventually progress to castration resistance. Castration resistance is progression of disease, either clinical (development of metastatic disease, progression of pre-existing disease) or biochemical (three consecutive rises in PSA levels above nadir) in the presence of castrate levels of circulating testosterone (\<50 ng/dL) ([@r27],[@r28]).

Indeed, the biochemical recurrence of PSA, an AR regulated gene measured by serum levels, is evidence that CRPC is not hormone-insensitive. When adding first generation anti-androgens, such as flutamide or bicalutamide, to the treatment regimen of patients with advanced or metastatic disease, a decrease in serum PSA is often initially noted, indicating a response to direct AR blockage ([@r29],[@r30]). However, serum PSA levels will again rise despite anti-androgen therapy, suggesting that the agent has begun functioning as an AR agonist; this is validated by the PSA decrease noted with anti-androgen withdrawal ([@r31],[@r32]).

Further evidence for the critical role of the androgen axis in the development of CRPC lies in the finding that, despite castrate levels of serum testosterone, there remains a higher level of intra-tumoral androgens in CRPC compared to hormone-naïve prostate cancer ([@r18]-[@r21]). Recent studies have demonstrated that intra-tumoral androgen levels in CRPC are similar to those of eugonadal men, and in some cases even increased ([@r22],[@r33]).

The AR persists in CRPC cells, and the re-activation of this axis by the following mechanisms appears to drive progression to castration-resistance.

AR dependent mechanisms of resistance leading to CRPC
=====================================================

The majority of mechanisms identified leading to castration-resistant are mediated by AR or the androgen axis. As seen in [*Figure 1*](#f1){ref-type="fig"}, they can be categorized into five main subsets.
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AR amplification and mutations/hypersensitivity pathway/promiscuous pathway
---------------------------------------------------------------------------

Low levels of androgen persist despite androgen blockade with ADT. Within this microenvironment, a subset of cells develop sensitivity to these low levels of androgens either through amplification of the AR (hypersensitivity pathway) ([@r34]) or development of AR mutations that lead to activation by molecules other than androgens (promiscuous pathway) ([@r35],[@r36]).

Amplification of the AR has been identified in a significant portion of CRPC cell lines, ranging from 30-80% ([@r37],[@r38]). This finding is uncommon in hormone naïve prostate cancer and may be due to selective outgrowth of CRPC cells ([@r36]). This amplification enables CRPC to be hypersensitive to low level of androgens, which promotes progression of disease ([@r35]). As 20% of CRPC metastases have evidence of AR amplification, which is absent in hormone-naive metastatic disease, it may also contribute to metastases. In addition, recent studies have shown that exogenous overexpression of AR can lead to CRPC.

Related to this concept, a substitution of valine with leucine at codon 89 results in increased 5α-reductase levels in a subset of CRPC. This results in higher levels of DHT despite low circulating levels of testosterone. This mutation is more commonly observed in the African-American population, and has been associated with more aggressive, early onset prostate cancer ([@r39],[@r40]).

There have been various point mutations identified in the *AR* gene itself that lead to increased AR activity in the presence of low levels of androgens as well as non-androgenic steroids, such as progesterone, hydrocortisone, estradiol, and certain AR antagonists. The substitution of threonine with alanine at codon 877 in LNCAP cells ([@r41],[@r42]) and the substitution of histidine for tyrosine in CWR22 cells ([@r43],[@r44]) are well described in the literature; other examples include L701H, V715M, W741C ([@r45]-[@r47]). While most of the mutations are predominantly in the LBD, mutations in the NTD and DNA-binding domain were also identified ([@r48],[@r49]).

Co-activators and co-repressors
-------------------------------

Over 150 different molecules have already been identified as co-activators and co-repressors for AR ([@r10]). The AR normally recruits a series of coregulator complexes, which can function to either enhance (co-activators) or repress (co-repressors) transcriptional activity. Many of these coregulators are enzymes that serve to modulate other proteins in the complex, either through phosphorylation, methylation, acetylation or ubiquitylation, but they have also been identified as molecular chaperones, recruiters of transcriptional machinery and RNA splicing regulators ([@r50]-[@r52]).

One coactivator, FKBP51, which is also an AR target gene, was found to be upregulated in relapsed LAPC-4 tumors grown in castrate mice ([@r53]). It promotes formation of a superchaperone complex by regulating the recruitment of p23, a co-chaperone, to ATP-bound Hsp90, which in turns keeps AR in a conformation with high-affinity for ligand binding. This promotes androgen-stimulated transcriptional activity and growth.

The steroid receptor coactivators (SRC) are a class of AR coactivators capable of acetyltransferase activity, which in turn enhances AR-induced transcription by promoting formation of complexes between AR-associated enhancers/promoters and the transcription start site of AR target genes ([@r54]). The SRC class includes SRC-1, SRC-2 (TIF-2, GRIP-1, NcoA2), and SRC-3 (AIB). Xu *et al*. demonstrated that all three have been associated with prostate cancer progression ([@r55]). Ueda *et al*. identified SRC-1, when phosphorylated by MAPK under the influence of IL-6, was capable of both ligand-dependent and ligand-independent AR activation ([@r56]). SRC-3, in particular, tends to be over amplified in human cancers. Chung *et al*. demonstrated that SRC-3 is not overexpressed in androgen-dependent prostate cancer, but is overexpressed in poorly differentiated and more advanced prostate cancer, and is directly associated with prostate cancer progression---SRC-3 knockout mice were effectively arrested at the well-differentiated stage and unable to progress to poorer pathology ([@r57]).

Other important pathways include p300/CBP, which promotes androgen-independent IL-6 mediated AR activation in the presence of STAT3 ([@r58]), and LSD1 and JMJD2c, lysine demethylases that demethylate the histone H3 proteins and lead to increased AR induced transcription ([@r59]). Many of these molecules have demonstrated AR-dependent and AR-independent effects, since their interaction is not limited to AR. Co-repressor proteins, on the other hand, have been found at reduced levels in CRPC.

Aberrant activation (post-translational modification)/outlaw pathway
--------------------------------------------------------------------

While all the prior mechanisms mediate increased AR activity in the presence of ligand, ligand-independent AR activation is also an important mechanism of progression to castration-resistance. Various *in vitro* studies have suggested that multiple growth factors, cytokines, and kinase pathways increase AR signaling, thereby promoting progression to castration resistance in a ligand-independent manner ([@r60]). Identification and characterization of those ligand-independent pathways can lead to additional targeted therapies.

The NF-κB family of proteins has been established as an important component of the oncogenic pathway in multiple human malignancies. There are five distinct NF-κB proteins, including the well-studied p65/p50 heterodimer, which has been shown to be constitutively active in prostate cancer. Another of the NF-κB pathways, the p100/p52 pathway has been of recent interest. The processing of p100 to p52 via molecules such as lymphotoxin β, B-cell activating factor, CD40 ligand, and stat3 ([@r61]) in prostate cancer, leads to significant hyperplasia and induced castration-resistant growth. This was accomplished by limiting ADT mediated apoptosis and cell cycle inhibition, but was done so in the presence of continued AR expression and activation, which suggested that p52 may activate AR during the progression of CRPC. p52 mediated its effects in an AR dependent manner by interacting directly with the NTD of AR. Downregulation of p52 in C4-2 cells led to the loss of constitutive activation of AR which suggested an androgen independent activation of AR ([@r62]).

The PI3K pathway is another important player in this process. The loss of the tumor suppressor PTEN protein, which is a negative inhibitor of the PI3K/AKT pathway, is identified in nearly all metastatic prostate cancers. Its activation has been associated with development of CPRC in various preclinical models ([@r63]-[@r65]). PI3K, specifically the p110β isoform, has been strongly associated with prostate cancer growth and progression, through basal activation of AKT in prostate cancer models. The PI3K/AKT pathway is downstream of key receptor tyrosine kinases (RTKs) such as EGFR, IGFR, c-met, but some studies suggest independent activation of this pathway ([@r66]). While it is also upstream of some critical signaling proteins, such as mTOR, it has also been found that AKT directly phosphorylates AR at two locations, Ser-217 and Ser-791, particularly in a castrate-state, though the clinical significance is not yet certain ([@r67]).

Src kinase, the key member in the family of non-RTK called Src family of kinases (SFK), has been a focus of our lab and our collaborators. Src, in the 25 years since its discovery as the first proto-oncogene identified, has been targeted in the treatment of multiple other malignancies ([@r68],[@r69]). Our research into the role of Src in prostate cancer identified Src as a key molecule in multiple pathways that allow for progression of prostate cancer ([@r70],[@r71]). Src is expressed in commonly used CaP cell lines CWR22Rv1, DU145, LAPC-4, LNCaP, and PC-3. As Src is not constitutively active, it has been difficult correlating Src protein expression levels with cell proliferation or aggressiveness *in vitro*. However, Src kinase is downstream of many important prostate-cancer influences---as it is activated by growth factors, cytokines, chemokines, and gastrin-releasing peptide, it has a pleiotropic effect on prostate cancer ([@r68],[@r70],[@r71]). Our laboratory group demonstrated that higher relative Src activation was associated with worse prostate cancer phenotypes, specifically DU145 and PC3, and the use of a novel SRC inhibitor AZD0530 helped elucidate a few of the pathways mediated by Src in prostate cancer cell lines ([@r70]). Activation of Src kinase has been linked to androgen-independent cell growth ([@r72]-[@r74]), inhibition of anti-apoptotic pathways ([@r75]-[@r77]), cell migration and adhesion ([@r73]), and tumor invasion ([@r78]), among other aspects of prostate cancer cell biology. Based on this preclinical data, AZD0530 (saracatinib) was taken to phase II clinical trial, but it was demonstrated to have minimal clinical efficacy as monotherapy ([@r79]). Lack of clinical efficacy was also noted with dasatinib; in the phase III clinical trial of docetaxel with dasatinib or placebo in chemotherapy-naïve CRPC patients, there was no improvement in overall survival ([@r80]). Other non-tyrosine kinases, such as Btk and Etk within the Tek-family of non-tyrosine kinases, are being targeted as well; recent work by Guo and colleagues demonstrated that CTN06, a novel dual inhibitor of Btk and Etk, induced apoptosis and autophagy, and also re-sensitized cell lines to docetaxel ([@r81]).

Growth factor pathways, such as IGF and KGF, bind and activate AR in a castrate state. Growth factor receptors, such as IGF-1R, IL-6R, and EGFR, control critical downstream growth and survival pathways such as MAPK, PI3K/AKT, and STAT signaling. Various RTKs, such as Her-2/neu, EGFR, and IGR-1R, enhance AR stability and activity, and in some cases, promote androgen independence. Her2/neu, for example, was found to promote xenograft cell growth via Ack1-kinase, which phosphorylates AR at tyrosine-267 and activates it ([@r82]). Targeting these pathways has shown some promise---cabozantinib (XL-184) inhibits tyrosine kinases of c-Met and VEGF, and in phase II clinical trial, demonstrated significant benefit specifically for CRPC patients with bone metastases; However, it did not reach its primary endpoint (bone pain alleviation) in phase III trial, with no significant difference in bone pain alleviation between the treatment and control (mitoxantrone/prednisone) arms.

Altered steroidogenesis
-----------------------

CRPC develops in the presence of castrate-levels of circulating androgens. However, intra-tumoral levels of androgens in CRPC models have been established to be the same as or even higher than in eugonadal men, suggesting that there is alternative androgen production ([@r18]-[@r22],[@r33]). This is likely due to adrenal production, specifically of androgen precursors of adrenal origin such as dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S), which can be converted to the highly active DHT via a "backdoor" pathway ([@r83],[@r84]).

DHEA and DHEA-S, produced by the adrenal gland, are not affected by ADT and are still found in circulation. The molecules are converted to androstenedione (AD) either in the prostate or adrenal gland by 3βHSD, encoded by HSD3B. There are 2 isoforms, 3βHSD1 in the prostate and peripheral tissues, 3βHSD2 in the adrenal gland ([@r85]). The subsequent conversion from AD to DHT, in the absence of ADT, typically goes through testosterone as an intermediary, and requires 17βHSD3 and AKR1C3 (encoded by HSD17B3 and AKR1C3 respectively) and steroid-5α-reductase (two isoforms, encoded by SRD5A1 and SRD5A2). However, in the presence of ADT, the sequence can be reversed, leading to 5α-AD (5α-dione) serving as the intermediary between AD and DHT, bypassing testosterone completely. This alternative pathway, referred to as the "5α-dione" pathway, has been demonstrated to predominate in CRPC ([@r86],[@r87]).

In addition to utilization of weak adrenal androgens in the 5α-dione pathway, recent assessment of CRPC cells has identified increased expression of steroidogenic enzymes such HSD3B1, HSD3B2, HSD17B3, AKR1C3, and SRD5A1 ([@r20],[@r87]-[@r89]), which may contribute to *de novo* production of steroids and androgens. Up-regulation of SRD5A1 and concurrent down-regulation of SRD5A2 leads to higher levels of 5α-reductase-1, for which AD is a better substrate than testosterone ([@r90]-[@r92]). What drives the changes in transcription of these steroidogenic enzymes? Many single-nucleotide polymorphisms have been identified within the above enzymes, especially HSD3B1 and HSD3B2 ([@r93]), but the clinical significance of these is not yet clear.

AR variants
-----------

A more recent development has been the identification of splice variants of the AR (AR-Vs), which are constitutively active, typically due to the loss of the C-terminal LBD ([@r94]-[@r97]). Indeed, the amplification of AR seen in CRPC may contribute to the development of the splice variants. Most CRPC cell lines demonstrate low levels of AR-V, but 22RV1 express levels similar to full-length AR ([@r44]).

The functional implication of these variants is not yet fully understood. Direct measurement of splice variants has been limited by the lack of variant-specific antibodies, leaving only secondary assessment via RNA levels. ARV7 is the only variant that has a suitable antibody for staining, and immunohistochemistry staining has established increased expression in CRPC ([@r95],[@r96]). However, transcribed RNA levels may not be completely reflective of protein levels. This suggests some post-translational control that has not yet been fully elucidated.

However, Hörnberg *et al*. reported high levels of splice variant expression in bone metastases compared to hormone-naïve prostate cancer, and that it led to CRPC and poorer prognosis ([@r98]). This study also demonstrated a discrepancy between RNA levels and protein levels, contributing to the difficulty in determining splice variant significance in CRPC development and progression.

The predominant variants are ARV1, ARV7 and ARV 567. Of the variants, ARV7 has been studied most extensively ([@r95],[@r96]). As described above, it lacks the LBD, is located in the nucleus, and is constitutively active. It has been show to regulate both AR-regulated genes and a unique set of AR-independent genes ([@r96]), suggesting it has an overlapping but distinct role compared to full-length AR in prostate cancer cells ([@r94]).

A recently discovered variant, ARV8, actually lacks a DNA-binding domain. Therefore, it remains in the plasma membrane and its constitutive activity is limited to activation of cell signaling pathways ([@r99]). For example, Yang *et al*. demonstrated increased AR phosphorylation via an EGF-mediated SRC activation in the presence of this variant; its subsequent knockdown was associated with loss of this phosphorylation.

Mechanisms of resistance to current CRPC treatments
===================================================

Based on this understanding of the development of CRPC, there are now approved medications for the management of patients who are castration-resistant. However, despite these new agents, all patients will eventually progress in their disease. Understanding the means by which prostate cancer overcomes these treatment modalities will help identify new treatment options.

Below, we will address the primary agents currently available, focusing on their mechanism of action and current knowledge about the resistance to their function. [*Figure 2*](#f2){ref-type="fig"} provides an overview of the current and experimental agents affecting the androgen axis. As can be expected, there is crossover in many of these mechanisms, with these shared pathways being potentially significant future targets.
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Docetaxel
---------

Docetaxel is the current standard of care for patients who have progressed to castrate-resistant prostate cancer. SWOG 9916 and TAX327 demonstrated a 3-month survival advantage with docetaxel over mitoxantrone in CRPC patients ([@r100]-[@r102]), and until recently, it was the only approved primary therapy for CRPC. The recent CHAARTED trial, however, may have demonstrated a role for docetaxel as an initial treatment option for hormone-naïve prostate cancer in conjunction with ADT, as the combination was found to have a 17-month survival advantage ([@r103]).

Docetaxel is a well-known and studied chemotherapeutic agent used in the treatment of a variety of malignancies. It is an anti-mitotic chemotherapeutic agent that works by binding the β subunits of tubulin in microtubules, thereby stabilizing them and preventing the depolymerization required for mitosis ([@r104]-[@r106]), which induces apoptosis. In CRPC specifically, docetaxel leads to phosphorylation of bcl-2 (B-cell lymphoma 2), which causes caspase activation and apoptosis *in vivo* and *in vitro* ([@r107],[@r108]). Additionally, AR expression is reduced in docetaxel-treated CRPC cells and is thought to be due to AR nuclear localization and inhibition of signaling ([@r109]).

Drug-efflux in CRPC enables resistance to docetaxel. Multi-drug resistance proteins (MDRP) are well described in the literature, and include P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BRCP). These molecules cause active efflux of multiple therapeutic agents. DU145 and 22RV1 cell lines, when made docetaxel-resistant, have been found to over-express P-gp ([@r110]), while CRPC lines exposed to docetaxel have been found to have MDR1 genetic variations that are more docetaxel-resistant ([@r111]). Docetaxel-resistant CRPC lines also upregulate the class III β-tubulin isoform, which allows less taxane binding. Inhibiting class III β-tubulin restores docetaxel sensitivity in those same cells ([@r112],[@r113]). In addition, LNCAP derived docetaxel-resistant cells demonstrated an F270I mutation in the class I β-tubulin, which had stronger taxane binding at baseline ([@r114]).

While the above mechanisms are docetaxel-specific, other mechanisms of resistance have been identified. Docetaxel resistance has been linked to apoptosis pathways, specifically upregulation of p53 and activation of PAR1. p53 is an important cell cycle regulator, often found over-expressed in prostate cancer. LNCAP cells over-expressing wild type p53 are more resistant to docetaxel activity than DU145 and PC3 cell lines, which have reduced or no p53 activity ([@r115]). Zhu *et al*. demonstrated this in docetaxel-resistant C42B cells *in vitro*---cells treated with docetaxel had p53 phosphorylation and activation, but taxane-resistant C42B demonstrated no phosphorylation ([@r116]). PAR1, through NF-κB activation, has been shown to reduce docetaxel-induced apoptosis ([@r117]).

In addition to blocking docetaxel-induced apoptosis, docetaxel's anti-mitotic activity itself directly initiates survival pathways in prostate cancer cell lines. Binding to the microtubules initiates pathways such as c-Jun N-terminal kinase (JNK), which in turns leads to activation of various transcription factors such as STAT-1, STAT-3, and NF-κB. Knockdown models of these transcription factors have been shown to be more sensitive to docetaxel-cytotoxicity ([@r115],[@r118]).

Over-expression of cytokines and chemokines, such as IL-6, IL-8, and CCL-2, and chaperone molecules, such as HSP27 and HSP90, have been associated with docetaxel resistance, but no clinically significant inhibitors of these pathways have yet been identified. OGX-011, a second-generation antisense drug that inhibits the secretion of clusterin, a chaperone protein, was administered in conjunction with docetaxel in phase III trials, but did not meet its primary endpoint. Its activity focuses on CLU, a key protein that exists in two forms: nuclear CLU (nCLU) and secreted CLU (sCLU)---nCLU promotes docetaxel-mediated cell death while sCLU prevents it ([@r119],[@r120]). Upon initiation of chemotherapy, especially docetaxel in prostate cancer cells, there is a shift in the balance towards sCLU, thought to be attributed to STAT-1 activation ([@r110],[@r121]). However, inhibition of sCLU using antisense oligonucleotide re-sensitizes the cells to docetaxel ([@r121],[@r122]).

Our lab group identified \>1,600 genes that had altered expression in taxane-resistant C42B cells, with approximately 52% being upregulated. From this subset, we recently identified ABCB1, which belongs to the ATP-binding cassette (ABC) transporter family, among the top upregulated genes in the taxane-resistant cells. ABCB1 was highly expressed in taxane-resistant C42B cells, but virtually undetectable in taxane-sensitive C42B cells. Inhibition of ABCB1 expression resensitized C42B cells to docetaxel, and this was then confirmed in the DU-145 cell line ([@r116]). Apigenen, a natural molecule in the flavone family identified by Shukla and Gupta ([@r123]), was demonstrated to help resensitize cells to docetaxel therapy.

Abiraterone and androgen synthesis inhibitors
---------------------------------------------

Abiraterone acetate (Zytiga) is a molecule structurally similar to pregnenolone that acts as an irreversible inhibitor of cytochrome p450, family 17, subfamily A, polypeptide 1 (CYP17A1). CYP17A1 is a member of the cytochrome p450 class of enzymes that serve as a catalyst for the oxidation of a variety of molecules. It has two consecutive enzymatic functions in the steroidogenesis pathway that contribute to the conversion of pregnenolone to DHT. Loss of CYP17A1 activity causes significant loss of androgen production in the peripheral organs, particularly adrenal androgens. It has been found to be 10-30 times more potent than ketoconazole, which is a non-specific inhibitor of p450 enzymes and previously has been used to generate rapid androgen ablation ([@r106]). The phase III trial COU-AA-301 demonstrated a 3.9-month survival benefit of abiraterone/prednisone over placebo/prednisone in patients who had progressed on docetaxel therapy ([@r124]). The subsequent COU-AA-302 trial demonstrated benefit in the pre-chemotherapy space, with improved radiographic progression free survival, time to initiation of chemotherapy, and a trend towards improved overall survival ([@r125]).

Altered steroidogenesis was discussed as one mechanism by which CRPC develops. While abiraterone-naive CRPC cell lines utilize the "5α-dione" pathway to generate intra-tumoral DHT by bypassing testosterone, they are still dependent on adrenal androgens. By irreversibly inhibiting this critical upstream enzyme in the steroidogenesis pathway, abiraterone effectively causes a significant decrease in intra-tumoral androgen levels by preventing production of adrenal androgens.

However, despite its effectiveness in inhibiting the steroidogenesis pathway ([@r126]), abiraterone's effect is incomplete. Attard *et al*. demonstrated that while most urinary androgen metabolites and serum androgens were suppressed, the inhibition of CYP17 led to higher levels of urinary metabolite 3α5α-17HP, which correlated with the excretion of androsterone---which is the primary metabolite of 5α-reducted androgens such as DHT ([@r127]). This suggests that the use of abiraterone may push 17-hydroxyprogesterone towards the "5α-dione" pathway.

As can be expected, over-expression or mutations of CYP17A1 may also contribute to abiraterone resistance ([@r128]). Chang *et al*. demonstrated that the HSD3B1 (1245C) mutation previously mentioned as contributing to progression to CRPC has also been found in abiraterone-resistant xenograft models, though the clinical significance of this still needs to be elucidated ([@r93]). Mostaghel *et al*. demonstrated that abiraterone-treated cell lines responded with increased expression of CYP17A1, as well as increased expression of enzymes in the steroidogenesis pathway, including AKR1C3 and HSD17B3 ([@r129]).

Other androgen synthesis inhibitors are in development at this time, including TAK-700 (Orteronel) and VT-464 (Viamet), both of which are more selective for the 17, 20-lyase inhibition ([@r130]). TAK-700 is further in development, currently accruing for another phase III clinical trial, this time assessing efficacy in chemotherapy-naive CRPC patients; the initial phase III study in patients who had been treated with docetaxel demonstrated an improvement in radiographic progression-free survival (HR 0.755), but it did not meet the primary endpoint of improvement in overall survival (HR 0.894) ([@r130]).

Enzalutamide and androgen receptor (AR) inhibitors
--------------------------------------------------

In response to the many AR mediated mechanisms of resistance found leading to development of CRPC, there has been development of a new generation of androgen-receptor signaling inhibitors. The main agent in this class is enzalutamide (MDV-3100, ENZA, Xtandi), which has been demonstrated to have a multi-pronged approach---preventing testosterone binding to AR, AR nuclear translocation, AR binding to DNA, and co-activator recruitment ([@r106]). While the AFFIRM III trial demonstrated a 4.8-month survival benefit over placebo in CRPC patients who had failed docetaxel and the PREVAIL trial demonstrated an overall survival and radiographic progression-free survival over placebo in chemotherapy-naïve CRPC patients ([@r131],[@r132]), not all the patients benefited from treatment---a subset of patients continued to progress, indicating that there are significant resistance mechanisms that need to be identified and addressed.

One mechanism by which CRPC develops resistance to enzalutamide, and potentially other treatment modalities, is the process of autophagy. Autophagy is a catabolic process that, besides being constitutively active at a low basal rate, is activated in response to stressors, allowing cells to use lysosomal-mediated degradation of cellular proteins and organelles to regenerate energy ([@r133]-[@r135]). Autophagy can be used by cancer cells to prolong their survival under harsh conditions of metabolic stress in the tumor microenvironment induced by various treatment modalities, but excessive or deregulated autophagy can push the cells toward autophagic cell death or type-II programmed cell death ([@r136],[@r137]). Indeed, androgen deprivation has been shown to induce autophagy, and while the exact mechanism is unknown, suppression of mTOR appears to play a critical role ([@r135],[@r138]). Prior studies, by our group and others, have established that administration of autophagy inhibitors, either as monotherapy or in conjunction with established therapies, has had effective cytotoxic result. We demonstrated that the use of clomipramine and metformin, both clinical autophagy inhibitors, significantly increased the cytotoxicity associated with enzalutamide *in vitro* and in mouse models---the enzalutamide/clomipramine combination decreased tumour size by 91%, compared with a 78% decrease with enzalutamide/metformin ([@r135]). There are currently many ongoing clinical trials assessing the role of autophagy inhibitors as concomitant therapy ([@r139]), including a study at our institution that has recently been approved to assess metformin and enzalutamide combination therapy.

AR point mutations are also important mechanisms of resistance to enzalutamide, just as in the development of CRPC. The Phe876Leu mutation in the LBD of AR has been reported to make enzalutamide into an agonist of AR, though the clinical relevance of this change has not been documented ([@r140],[@r141]). Similar effects were noted for the first generation anti-androgens bicalutamide and flutamide.

Another proposed mechanism is the "glucocorticoid receptor take-over" pathway. Glucocorticoid receptors are nuclear receptors similar in structure to the AR. Glucocorticoids initially have a suppressive effect on prostate cancer, and indeed, are often given in conjunction with early treatments of CRPC, including chemotherapy and abiraterone. However, the DNA binding domain of the glucocorticoid receptor is very similar to the DBD of the AR ([@r142],[@r143]), and the glucocorticoid receptor has been shown to bind to many AR regulated genes, suggesting its upregulation in patients treated with chemotherapy or ADT may contribute to enzalutamide resistance ([@r144]).

Many of these mechanisms may also affect upcoming androgen-receptor inhibitors in a similar fashion. For example, ARN-509, another novel AR antagonist which is currently in the accrual phase of a multi-center phase III clinical trial, has been shown to be susceptible to the same AR F876L mutation that converts it to an agonist ([@r145]). Other agents currently being developed include ODM-201.

Targeting the androgen receptor (AR): the next step in prostate cancer therapy
==============================================================================

As recently published in the *New England Journal of Medicine*, Antonarakis and collaborators demonstrated that 20-40% of circulating tumor cells in CRPC patients treated with abiraterone and enzalutamide have ARV7 constitutively active ([@r146]). More importantly, however, they demonstrated in this prospective trial that the subset of men with ARV7 in circulating tumor cells had a significantly lower PSA response rate, shorter progression-free survival and overall survival compared to men without ARV7 expression. This study, our own research ([@r62]), and studies by other groups ([@r94],[@r145]-[@r147]) demonstrate that ARVs are an important mechanism of resistance to newer CRPC agents. Liu *et al*. demonstrated that AR-V7 was present in a number of prostate cancer cell lines and that it was able to activate the PSA promoter in LNCaP and PC3 cells in the absence of androgen ([@r148]). With the loss of the LBD on the AR as seen in ARV-7, CRPC cell lines overcome the loss of circulating and intratumoral androgens mediated by abiraterone. Loss of the LBD, and concurrent ligand-independent binding of AR to ARE's, is thought to be the underlying mechanism of resistance to enzalutamide. Li *et al*. demonstrated that knockdown of AR-V limited androgen-independent growth rate of CWR22Rv1 cells and restored responsiveness to anti-androgens ([@r147]).

With the growing body of evidence pointing to the important role of ARV's in the development of resistance and the concurrent finding that many of the current mechanisms of progression to CRPC involve alterations in the AR pathway, targeting the AR appears to be the next major step in prostate cancer therapy.

Our lab previously identified niclosamide, used clinically to treat helminth infections, as an inhibitor of ARV7, by promoting its degradation; co-treatment with enzalutamide demonstrated a synergistic response ([@r148]). Similarly, we also established that miR-let-7c, a microRNA of the let-7 family, antagonizes AR expression via c-myc degradation, leading to inhibition of prostate cancer proliferation ([@r149]). Others have also started to focus on the AR itself as a target for therapy---either reducing its expression or promoting its degradation. Lai *et al*. have identified ASC-J9, a novel AR degradation enhancer currently utilized clinically for other pathologies ([@r150]). Sadar and colleagues have been focusing on EPI-001, a small molecule that inhibits the N-terminal domain (NTD), which is present on both wild-type AR and AR variants ([@r151]).

Perhaps by targeting the AR and its variants, we may be able to overcome the deficiencies of current CRPC treatments.

Conclusions
===========

Prostate cancer, especially locally advanced and metastatic disease, continues to be a burden on the healthcare system. While the prognosis is good for men diagnosed with localized disease, the prognosis remains poor for men with more advanced disease. All current therapies, from ADT to chemotherapy, merely slow the progression of disease, but all patients inevitably progress on therapy. Understanding the mechanisms by which these patients develop resistance to ADT, then subsequently to docetaxel, abiraterone, and enzalutamide, is important to identify future targets of therapy.
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